November 8, 2017

Trump’s Opioid Announcement May Be Enough to Bring Increased Litigation

By David B. Sudzus and Russell J. Chibe

Chicago partner Dave Sudzus and associate Russ Chibe authored an article, “Trump’s Opioid Announcement May Be Enough to Bring Increased Litigation,” for the Chicago Daily Law Bulletin. In light of President Trump’s declaration of the nation’s opioid epidemic as a “national health emergency,” they examined the administration’s potential influence on public perception and litigation cases involving pharmaceutical manufacturers.

Dave and Russ discussed the administration’s conflicting statements on working with pharmaceutical companies to develop innovative technologies while also stating that the U.S. Department of Justice would “be bringing some very major lawsuits against people and against companies that are hurting our people.” Dave and Russell wrote that such statements concerning pharmaceutical manufacturers could affect pretrial publicity, jury pools and outcomes of litigation. They also noted that the “declaration of a public health care emergency does not itself seem to encourage lawsuits from public entities or attorneys general.”

Read “Trump’s Opioid Announcement May Be Enough to Bring Increased Litigation.”

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.